Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License ...

The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application for Gazyva® ...

Supported by the phase 3 ALLEGORY trial, the application moves obinutuzumab closer to becoming a new standard for patients with active, autoantibody-positive SLE.

Objective The multinational ERYTHRO ( NCT06046534) study investigated the experience of patients with moderate-to-severe SLE ...

Belimumab demonstrates notable efficacy for enhancing treatment outcomes among adults with active systemic lupus erythematosus when added to standard therapy. Belimumab demonstrates notable efficacy ...

The following transcript is automatically generated and may contain typos or misspellings. Please listen to the episode for the most accurate language. Dr. Susan Manzi 0:00 Hello everyone. I'm Dr.

A Phase II study was subsequently performed by the LBSL02/99 group, which enrolled 449 patients who met American College of Rheumatology (ACR) diagnostic criteria for SLE, had active SLE disease and ...

Early and sustained adherence to antimalarials may help prevent RA and SLE disease flares, cardiovascular complications, and reduce future hospital use and costs.

Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License ...